This study uncovers a significant link between blood-brain barrier disruption and cognitive impairment in lung cancer patients, indicating a critical area for therapeutic intervention. As cognitive health becomes increasingly recognized in oncology, pharma strategy teams should consider the implications for treatment development and patient care. Regulatory context from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) supports the near-term read. Assessment grounded in 9 ranked evidence items (6 high-relevance).